Op-ed piece from Dr. Andrew Tatarsky,  president of the

New Post Public Reply Private Reply Replies (0) Message Board
bellsandwhistles
Op-ed piece from Dr. Andrew Tatarsky,  president of the Division of Addiction of the New York State Psychological Association and founder and director of the Center for Optimal Living, an addiction treatment and professional training center in New York City. He has specialized in the field of substance use treatment for over 30 years. He slams addictive and abuse-prone Big Pharma drugs.

Medical marijuana is humane
By Dr. Andrew Tatarsky
Tuesday, January 28, 2014

As a psychologist who has specialized in substance use treatment for over 30 years, I have given a lot of thought to medical marijuana. Over the years, I have seen several patients who have used marijuana medicinally but have suffered — from potential criminal prosecution and the shame, stigma and fear that comes from using an illicit substance. Twenty states and D.C. now permit the use of medical marijuana. New York should join them.

I applaud Gov. Andrew Cuomo's recent acknowledgement of cannabis' medical value for some seriously ill people. However, the 1980 Olivieri Law that he is using, through which medical marijuana would be available through 20 hospitals around the state, has significant restrictions, preventing many patients who need the medicine from receiving it.

The Legislature is currently considering the Compassionate Care Act, which would create one of the best-regulated medical marijuana programs in the country. I urge Cuomo to work with the Legislature to enact this comprehensive legislation this session. Many of my colleagues in the addiction and mental health treatment communities support this bill, as reflected in endorsements by the New York State Psychological Association and its Division on Addiction.

Allowing the seriously ill access to safe and legal medical marijuana under their health care provider's supervision is, fundamentally, an issue of compassion and human rights . The medical value of cannabis is no longer a matter of dispute. The efficacy of cannabis for controlling certain conditions and symptoms is well-established in the scientific literature. And, compared to other prescription medications, like widely used opioid pain relievers, medical cannabis is relatively safe, having no known lethal dose and few side effects.

The Compassionate Care Act will ultimately make the job of drug treatment professionals like me easier. The worst dangers associated with medical marijuana come from forcing patients to seek medical marijuana on the illicit market, with potentially devastating consequences — like untested and possibly contaminated product, lifelong criminal records, and shame and stigma from using an illegal substance.

It's time to acknowledge that our current efforts to prohibit marijuana use, by pushing an abstinence-only message and exaggerating the dangers, have failed. Marijuana use by young people can be a problem and should be discouraged, but denying those with debilitating medical conditions access to medical marijuana is not a winning prevention strategy.

When our young people learn that their drug education is filled with misinformation about marijuana, we lose credibility and damage our ability to teach them accurate information about the real dangers of marijuana and other drugs.

We need honest, reality-based drug prevention and treatment programs to reduce the problematic use of marijuana by children and adults alike.

In fact, another reason I support the Compassionate Care Act is because it would generate and earmark substantial funding for such prevention programs, which have unfortunately been devastated by cuts in recent years.

I am not suggesting that medical marijuana is the right choice for everyone. There are risks associated with using it, just as with any medication. Medical marijuana shouldn't be recommended for use in adolescents, unless there is a compelling medical need, and people with particular mental illnesses, especially schizophrenia, should avoid using it.

There is also the risk, in a small percentage of users, of overuse and addiction; those cases should be referred to mental health and substance use treatment professionals for assessment and treatment. But we can best assess our patients and address these risks by having an open and honest dialogue — something nearly impossible for most health care practitioners in New York right now.

Our responsibility as drug treatment providers is to work with our patients to help them create full, meaningful, and healthy lives.

We have long had to deal with helping clients who use potentially dangerous and addictive medications (i.e., from Big Pharma) to treat illnesses, and we do so because no one should have to suffer needlessly.

Medical marijuana is a fundamental matter of compassion, and bringing it into a safe, regulated and de-stigmatizing system will solve far more problems than does our current system of criminalizing our sickest and most vulnerable citizens.
http://www.timesunion.com/opinion/article/Med...182570.php

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 93

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Updated Category News Views 40

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 136

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 192

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 121

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 74

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Chemours Faces Class Action Over Fraud Allegations

Updated Category News Views 246

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 183

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 208

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 150

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading

Top 5 Most Recently Viewed Articles

Core Molding Technologies Set to Engage Investors at Roth

Updated Category News Views 111

Core Molding Technologies at Industry Conferences Core Molding Technologies, Inc. is excited to announce its upcoming participation in the prestigious Annual Roth Conference. This event is a fantastic opportunity for the management team to engage directly with investors and showcase the innovative solutions the company offers. Investors Meet Management During the...

Continue Reading
Minerals Technologies Announces Dividend for Shareholders

Updated Category News Views 174

Minerals Technologies Declares Quarterly Dividend Minerals Technologies Inc. (NYSE: MTX), a leading figure in the specialty minerals industry, has made an important announcement regarding its financial practices. The company has officially declared a regular quarterly dividend of $0.11 per share on its outstanding common stock. This decision reflects their commitment to...

Continue Reading
Converge Technology Solutions Recognized at Ingram Micro Summit

Updated Category News Views 104

Converge Technology Solutions Receives Prestigious Award Converge Technology Solutions Corp. (TSX: CTS) is excited to announce that the company has been named Solution Partner of the Year by Ingram Micro, a notable player in the global technology industry. The accolade comes during the recent Ingram Micro ONE Innovation Summit, highlighting Converge's exemplary...

Continue Reading
LONGi Solar's Strategic 102MW Partnership Elevates Nordic Energy

Updated Category News Views 174

LONGi Solar Partners for a Sustainable Future LONGi Solar has embarked on a significant journey by entering a strategic partnership with a prominent Finnish energy company. This collaboration centers on supplying 102MW of the advanced Hi-MO X10 back contact modules, marking a pivotal moment for LONGi as it enhances its footprint in the Nordic energy market. This agreement...

Continue Reading
Bascom Arizona Ventures Expands Portfolio with $53.4 Million Deal

Updated Category News Views 116

Bascom Arizona Ventures Acquires Multifamily Property Bascom Arizona Ventures, LLC (BAZV), an affiliate of a prominent private equity firm based in California, has successfully acquired the Retreat at Speedway, a multifamily property that features 304 units. The acquisition, valued at $53.4 million, translates to approximately $175,658 per unit. With this transaction,...

Continue Reading